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Protein kinase C (PKC) is a family of phos-
pholipid-dependent serine/threonine protein
kinases that are found in almost all eukary-
otes and in high concentrations in neural tis-
sues (1–3). Evaluation of the functions of the
various PKCs is an active area of research,
but it has been established that PKC plays
important roles in the nervous system. For
example, PKC is involved in the regulation
or modulation of neurotransmitter release
(4,5), synaptic and neuronal plasticity (6,7),
neuronal ion channels (8), cerebral microvas-
cular function (9), and cognition (10–12).
Alterations in PKC-dependent phosphoryla-
tion have been found in the brains of patients
with Alzheimer disease (13,14), suggesting
that PKC may also be involved in the patho-
genesis of neurodegenerative disease.
Considerable research has focused on the
interactions between lead and calcium in the
activation of PKC. For example, picomolar
concentrations of lead can substitute for
micromolar concentrations of calcium in the
activation of PKC, as assessed by PKC
enzyme activity assays (15). To date, PKC is
the only cellular target known to be affected
by lead in the range of free lead concentra-
tions of 2 × 10–11–3 × 10–11 M (16–18).
Translocation of PKC from the cytosol to the
membrane has been observed in immature
microvessels, rat glioma cells, and bovine
endothelial cells after exposure to lead (9).
Continuous lead exposure was implicated in
interference with training-induced transloca-
tion of PKC from the cytosol to the mem-
brane in the rat hippocampus (19). Recently,
lead exposure during development was
shown to decrease membrane-associated
PKC in the rat hippocampus and frontal cor-
tex and to potentiate phorbol-12,13-dibu-
tyrate (PDBu)-activated PKC translocation;
PDBu is a phorbol ester that binds to the
diacylglycerol binding site on PKC, causing
PKC translocation from the cytosol to the
membrane (10).
Although a number of experimental stud-
ies have evaluated interactions between lead
and PKC, none has examined the inﬂuence
of PKC on neurobehavioral function in
adult humans. We previously reported an
association between PKC activity and lead
exposure in current lead workers; specifi-
cally, we found that higher tibia lead levels
and longer job durations were associated
with higher in vivo PKC activity, as assessed
by a back-phosphorylation assay (20). We
designed the current study to determine
whether in vivo PKC activity in erythrocytes
is associated with neurobehavioral function.
We also evaluated whether PKC activity
modiﬁes the relationship between blood lead
levels and neurobehavioral test scores, allow-
ing inferences to be made about the mecha-
nisms of lead neurotoxicity in adults. 
Materials and Methods 
Study design and subject selection. From
October 1997 to August 1999, we recruited
803 lead workers and 135 nonexposed con-
trols in the Republic of Korea for a 4-year
prospective study of the health effects of lead
(21). From April to July 1998, we selected
from among these lead workers 212 consecu-
tively enrolled subjects (156 males and 56
females) in four lead storage battery plants
for a study of erythrocyte membrane protein
phosphorylation. This back-phosphorylation
study was conducted in only a subset of sub-
jects because of the technical difﬁculty of the
assay and because a power calculation indi-
cated that 200 subjects would be sufﬁcient to
assess study aims. The current study is a
cross-sectional analysis of data from the ﬁrst
year of the prospective study (October
1997–October 1998). The study subjects
were examined at Soonchunhyang University
Institute of Industrial Medicine in Chunan.
All subjects provided written informed con-
sent, and participation was voluntary. This
study was approved by Institutional Review
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At picomolar concentrations, lead activates protein kinase C (PKC). This activation has been
implicated in the neurotoxicity of lead. No prior study has evaluated the association of PKC activ-
ity with neurobehavioral function in humans. The purpose of this study was to determine
whether PKC activity is associated with neurobehavioral function or modifies the relationship
between blood lead levels and neurobehavioral test scores. In this cross-sectional study of 212 cur-
rent lead workers in the Republic of Korea, we assessed blood lead levels, neurobehavioral test
scores, and PKC activity. PKC activity was determined by measuring the levels of phosphoryla-
tion of three erythrocyte membrane proteins (spectrin and the 52-kDa and 48-kDa subunits of
band 4.9), using an in vitro back-phosphorylation assay. When linear regression was used to con-
trol for confounding variables, blood lead was a significant predictor of decrements in perfor-
mance on tests of psychomotor function, manual dexterity, and executive ability. In linear
regression models, back-phosphorylation levels were not associated with neurobehavioral test
scores, but when dichotomized at the median, back-phosphorylation levels modiﬁed the relation-
ship between blood lead and test scores. For spectrin and the 52-kDa and 48-kDa subunits of
band 4.9, 5, 2, and 5 of 14 interaction terms, respectively, had associated p-values < 0.10, all with
positive signs, indicating that blood lead was associated with worse test scores only in subjects
with lower back-phosphorylation levels. These data indicate that blood lead levels are associated
with decrements in neurobehavioral test scores, mainly in the domains of manual dexterity and
psychomotor function, but only in subjects with lower in vitro back-phosphorylation levels,
which is equivalent to higher in vivo PKC activity. We hypothesize that subjects with higher PKC
activity in the presence of lead may be more susceptible to the health effects of lead. Key words:
back-phosphorylation, blood lead, neurobehavioral function, protein kinase C, susceptibility.
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Data collection. All subjects completed a
standardized questionnaire, a medical history
questionnaire, an occupational history inter-
view, and a neurobehavioral test battery con-
sisting of examiner-administered tests;
underwent assessment of peripheral vibration
threshold with the Vibratron II tester
(Physitemp Instruments Inc., Clifton, NJ,
USA); and provided a 10-mL blood specimen
by venipuncture that was stored at –70°C as
whole blood, plasma, and erythrocytes (21). 
An occupational physician obtained the
medical history, and a trained psychologist
and a registered nurse performed the neu-
robehavioral testing. All study questionnaires
and instructions for data collection were
translated into Korean and then translated
back to English to assess the accuracy of the
translation. The standardized questionnaire
assessed demographic characteristics, educa-
tion, tobacco and alcohol use, detailed med-
ical history, subjective symptoms related to
lead exposure, and complete job history. 
Neurobehavioral test battery. We used the
World Health Organization Neurobehavioral
Core Test Battery (WHO NCTB) (22) and
several additional selected tests to assess neu-
robehavioral function. The digit symbol sub-
stitution test is a performance subtest of the
Wechsler Adult Intelligence Scale-Revised
(WAIS-R) and was used to assess executive
abilities, which require learning of associa-
tions (23). The digit span test is a verbal
subtest of the WAIS-R and the Wechsler
Memory Scale-Revised (WMS-R) and was
used to assess verbal memory and learning
(24). The Benton Visual Retention Test is a
test of short-term visual memory using geo-
metrical patterns. The Pursuit Aiming II test
was used to measure manual dexterity (25).
The simple reaction time test was used to
measure how fast subjects reacted to a visual
stimulus, an assessment of attention and psy-
chomotor speed (26). Simple reaction time
was assessed with the Standard Reaction
Time Tester (Software Science, Cincinnati,
OH, USA), consisting of 64 trials over 6
min with a static group of random interstim-
ulus intervals between 1 and 10 sec. The
Purdue pegboard test (Lafayette Instrument,
Model 32020, Lafayette, IN, USA) was sub-
stituted for the Santa Ana dexterity test of
the WHO NCTB and was used to measure
manual dexterity and executive abilities (27).
Trail-Making Tests A and B were used to
assess executive abilities (28). Raven’s col-
ored progressive matrices (Psychological
Corporation, San Antonio, TX, USA) were
used to measure visual reasoning and problem
solving, an assessment of intellectual develop-
ment (29). The Center for Epidemiological
Studies Depression scale (CES-D), consisting
of 20 questions translated into Korean, was
used to evaluate depressive mood and affect
during the past week (30). 
Laboratory measurements. Hemoglobin
was assayed by the cyanmethemoglobin
method (Coulter Model AcTB; Beckman
Coulter, Seoul, South Korea), and hematocrit
was measured by the capillary centrifugation
method (31). Blood lead levels were measured
with a Zeeman background-corrected atomic
absorption spectrophotometer (Hitachi
Z-8100 model; Hitachi Instruments, Tokyo,
Japan) using the National Institute of
Occupational Safety and Health standard
addition method (32) at Soonchunhyang
University Institute of Industrial Medicine, a
certified reference laboratory for lead in
Korea. The institute participates in quality-
control programs for industrial laboratories, a
regulation of the Korean government (33).
Zinc protoporphyrin (ZPP) levels were mea-
sured with a portable hematoﬂuorimeter (34).
Erythrocyte membrane preparation.
Venous blood was collected in a heparinized
vacutainer tube. Each sample was cen-
trifuged at 1,000 g for 20 min to separate the
erythrocytes. Plasma and buffy coats were
removed by aspiration, and cells were
washed 3 times with equal amounts of
saline. Erythrocytes were preserved by rapid
freezing in a cryopreservative (35). An equal
amount of cryoprotective additive solution
(28% glycerol, 3% mannitol, 0.65% NaCl)
was added to packed erythrocytes and thor-
oughly mixed. Erythrocytes were stored at
–70°C in Korea, transferred under dry ice to
the Kennedy Krieger Institute in Baltimore,
Maryland, USA, and then kept at –70°C
until erythrocyte membranes were prepared.
Appropriate isolation of erythrocyte
membranes is critical to the back-phospho-
rylation assay because the membrane com-
position depends on the preparation
method. Briefly, approximately 3–4 mL
glycerolized erythrocytes were thawed on
wet ice (36). Osmotic lysis was initiated by
adding 20 mM sodium phosphate buffer at
pH 7.4 to the erythrocytes to achieve an
erythrocyte-to-buffer ratio of 1:15 v/v. After
20 min on wet ice, the hemolysate was cen-
trifuged at 20,000 g for 40 min. The super-
natant fractions were decanted, and the
membrane proteins in the pellet were
washed 4 or 5 times with phosphate buffer
until the fraction was colorless. The mem-
brane proteins were resuspended in phos-
phate buffer, and the protein content of the
membranes was determined (37). Aliquots
of membranes were stored at –70°C until
use. 
Determination of back-phosphorylation
levels. An in vitro back-phosphorylation
assay was used to determine in vivo PKC
activity. The principle of this assay is that
proteins that were phosphorylated by PKC
in vivo will not undergo phosphorylation in
the in vitro back-phosphorylation assay after
addition of exogenous PKC. Therefore, the
levels of in vitro back-phosphorylation are
inversely related to in vivo PKC activity. 
Erythrocyte membranes were thawed at
4°C and sonicated for 30 sec on wet ice
(Sonifier Cell Distributor, model W185D;
Branson Ultrasonic Devices, Inc., Danbury,
CT, USA). Membrane proteins were diluted
with 20 mM phosphate buffer to 0.16 µg/µL
concentration. Phosphatidyl serine (PS;
BPS-578; Avanti Polar Lipids Inc., Alabaster,
AL, USA) was dried under nitrogen gas at
4°C, resuspended in 50 mM Tris/HCl (pH
7.4), and sonicated for 30 sec at 4°C. PDBu
(1 µg/µL) was added to PS to achieve con-
centrations of 0.0125 µg/µL and 0.25
µg/mL, respectively. A solution of cofactors
was made by taking equal volumes of
PS/PDBu, membrane protein, and 12 mM
CaCl2 and 30 mM dithiothreitol, both in 50
mM Tris/HCl (pH 7.4). 
[γ-32P]-Adenosine triphosphate (ATP) at
0.08 µCi/µL was freshly made in 45 mM
MgCl/150 µM ATP for each assay. PKC was
prepared at 0.1 unit/25 µL. To initiate the
reaction, 25 µL of cofactor solution, 25 µL of
[γ-32P]-ATP, and 25 µL of PKC were mixed.
The ﬁnal quantities of reactants were 1 µg of
membrane protein, 0.1 unit of PKC, and 2.6
µCi of [γ-32P]-ATP. 
Reaction mixtures were incubated at
30°C for 30 min in a heat block (VWR
Scientiﬁc Products, West Chester, PA, USA)
and terminated by adding an equal amount of
ice-cold acetone. The supernatant fraction
was removed by centrifugation at 20,000 g for
20 min at 4°C, and the pellets were isolated
and resuspended in 30 µL loading buffer.
Samples were boiled for 3 min and subjected
to SDS-PAGE. Gels were stained with
0.005% Coomassie Brilliant Blue solution (in
40% methanol, 7% acetic acid) overnight at
room temperature, then destained and dried. 
[γ-32P] incorporation into membrane
proteins was measured by phosphoimaging
with a bioimaging analyzer (Fuji BAS 2500,
Mac BAS version 2.5; Fujifilm Medical
Systems, Stamford, CT, USA) from dried
gels after the gel was exposed for 30 min to
an imaging plate (Fuji, BAS-IIIs). The incor-
porated radioactivity in the back-phosphory-
lation assay is expressed as units of
photostimulated luminescence (PSL).
Preliminary experiments revealed that
membrane proteins of molecular masses of
240, 230, 80, 52, and 48 kDa were phospho-
rylated by the exogenously added PKC.
Without addition of PKC, phosphorylation
was not observed. Based on molecular mass,
the 240- and the 230-kDa proteins were
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and the 52- and the 48-kDa proteins as the
two subunits of band 4.9 (38). Although
other proteins underwent phosphorylation by
PKC, spectrin and band 4.9 were observed
most consistently and were thus measured to
determine in vivo PKC activity.
Although the amount of protein sub-
jected to SDS-PAGE was approximately
equivalent for each sample (1 µg), we noticed
some variability between samples after the
gels were stained. For this reason, we mea-
sured the staining of spectrin by computer-
ized densitometry to determine the amount
of spectrin on each gel. The measured optical
density was used to adjust for the variability
in loaded protein in the statistical analysis.
Spectrin is composed of two subunits, α and
β, but we measured the optical density of
spectrin as one protein because the two sub-
units were difﬁcult to distinguish.
Assay variability and adjustment. We
observed variability in back-phosphorylation
levels in the same preparation of erythrocyte
membranes. To control for this variability, a
single standard sample was assayed on each of
the 7 days that experimental samples were
assayed. During the period, the intraday coef-
ficient of variation ranged from 10.9% to
27.6%, with a mean of 17.1%. However, the
interday coefﬁcient of variation of the stan-
dard sample was 33.9%. Thus, all samples
were adjusted by the ratio of the standard
sample on that date to the mean of all stan-
dard samples. This method of adjustment
controlled, at least in part, for interday
variability. All study samples were assayed in
duplicate on separate gels, and the mean of
the two results was calculated. The correla-
tion between duplicates was high (Pearson’s r
= 0.87, p < 0.001), and the mean percent dif-
ference between duplicates was 25.2%.
Statistical analysis. The two major objec-
tives of the analysis were to examine whether
in vitro back-phosphorylation levels, a surro-
gate for in vivo PKC activity, were predictors
of neurobehavioral test scores or effect modi-
fiers of the relationship between blood lead
levels and neurobehavioral test scores. Prior
analysis indicated that among the lead dose
measures [i.e., blood lead, dimercaptosuc-
cinic acid (DMSA)-chelatable lead, tibia lead
by X-ray ﬂuorescence], blood lead levels were
the strongest and most consistent predictors
of neurobehavioral test scores in this popula-
tion (21). Thus, analysis of effect modiﬁca-
tion by back-phosphorylation levels focused
on blood lead levels. 
We constructed separate linear regression
models for each neurobehavioral test, control-
ling for age, sex, job duration, and education.
To address the ﬁrst objective, we used linear
regression to separately model each neurobe-
havioral test in relation to back-phosphoryla-
tion levels for spectrin, and the 52-kDa and
48-kDa subunits of band 4.9 as explanatory
variables. To address the second objective, we
added cross-product terms between blood
lead and back-phosphorylation levels to each
model, adjusting for age, sex, job duration,
and education. For these models, we divided
back-phosphorylation levels at the median
into higher and lower groups. Four neurobe-
havioral tests (standard deviation of reaction
time, trails A, trails B, and CES-D) were log-
transformed to better approximate normality.
For consistency of presentation, we
selected the final regression models of neu-
robehavioral test scores with the same set of
confounding variables. Variables that were
considered potential confounders (i.e.,
tobacco and alcohol use, body mass index,
hemoglobin, hematocrit) were added in a for-
ward stepwise procedure and were retained in
the ﬁnal models if they were found to be pre-
dictors of neurobehavioral test scores or if
they signiﬁcantly changed the β coefﬁcient of
the back-phosphorylation or blood lead terms
in the models (a determination based on
change of both the magnitude and statistical
significance of the coefficient). To evaluate
nonlinear associations, we included linear and
quadratic terms for selected continuous vari-
ables in the models. Neurobehavioral test
scores were standardized so that a negative
regression coefﬁcient indicated worse perfor-
mance with increasing blood lead levels. 
We evaluated all regression models for
violation of the assumptions of linear regres-
sion. We also evaluated regression diagnostics
such as residual plots, added variable plots,
and variance inflation factors to determine
whether inﬂuential points, multicolinearity,
nonlinearity, departures from normality, or
nonhomogeneous variance accounted for the
study results. 
Results
The study participants had a wide range of
blood lead, tibia lead, and ZPP levels, rang-
ing from 5.4 to 69.3 µg/dL, 0.8 to 290.8 µg
Pb/g bone mineral, and 26 to 386 µg/dL,
respectively (Table 1). Back-phosphorylation
levels of spectrin, the 52-kDa subunit of
band 4.9, and the 48-kDa subunit of band
4.9 ranged from 29.5 to 1737.0 PSL units,
31.2 to 502.1 PSL units, and 35.8 to 576.5
PSL units, respectively (Table 1). 
Summary statistics for neurobehavioral
test scores can be found in Table 2. Males
had significantly better performance than
females on all neurobehavioral tests except
the Purdue pegboard, and older age was
consistently associated with lower neurobe-
havioral test scores. Education level and
tobacco and alcohol use were not signiﬁcant
predictors of neurobehavioral test scores.
Back-phosphorylation levels were not asso-
ciated with neurobehavioral test scores in
crude (Table 3) or adjusted analysis (con-
trolling for age, sex, job duration, and edu-
cation; data not shown). Blood lead levels
were significant negative predictors of neu-
robehavioral test scores in the domains of 
psychomotor function, manual dexterity,
and executive ability (Table 4).
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Table 1. Characteristics of 212 Korean lead workers, 1998.
Male Female
Characteristic (n = 156) (n = 56) p-Valuea
Age (years) 36.3 ± 0.8 47.0 ± 0.9 < 0.01
Exposure duration (years) 8.8 ± 0.6 6.2 ± 0.5 < 0.01
Education (years), no. (%) 0.61
≤ 6 36 (23.1) 14 (25.0)
7–9  40 (25.6) 12 (21.4)
10–12  69 (44.2) 27 (48.2)
≥ 13  11 (7.1) 3 (5.4)
Tobacco use, no. (%) < 0.01
Never/former 50 (32.1) 56 (100)
Current  106 (67.9) 0 (0)
Alcohol use (drinks per week), no. (%)  < 0.01
0 to < 1 41 (26.3) 42 (75.0)
≥ 1  115 (73.7) 14 (25.0)
Weight (kg)  62.2 ± 0.7 57.3 ± 1.2 < 0.01
Height (cm) 167.2 ± 0.5 153.6 ± 0.6 < 0.01
Body mass index (kg/m2) 22.2 ± 0.2 24.3 ± 0.5 < 0.01
Blood lead (µg/dL) 32.0 ± 13.0 19.8 ± 9.2 < 0.01
Tibia lead (µg Pb/g bone mineral) 37.8 ± 39.6 25.5 ± 14.7 0.03
ZPP (µg/dL) 68.7 ± 47.8 72.1 ± 29.7 0.61
Spectrin back-phosphorylationb 537.6 ± 25.3 549.4 ± 36.1 0.80
Band 4.9 (52 kDa) back-phosphorylationb 192.3 ± 5.9 216.2 ± 11.7 0.05
Band 4.9 (48 kDa) back-phosphorylationb 238.8 ± 6.6 253.6 ± 11.4 0.26
Spectrin quantity on gels, optical densityc 22.8 ± 0.8 22.8 ± 1.2 0.96
Values shown are mean ± SD except where indicated.
ap-Values were obtained by Student’s t-test for continuous variables and by χ2 test for categorical variables. bThe back-
phosphorylation levels were measured in units of PSL using a phosphoimager. cSpectrin quantity was measured in optical
density units using computerized densitometry after staining the gels with Coomassie Brilliant Blue.We then divided back-phosphorylation
levels at the median into high and low groups
for spectrin and the 52-kDa and 48-kDa
subunits of band 4.9. We then evaluated the
effect of back-phosphorylation levels on the
relationship between blood lead levels and
neurobehavioral test scores by adding cross-
product terms to the linear regression mod-
els. The signs of the β coefficients of the
interaction terms between blood lead and
back-phosphorylation levels of spectrin, the
52-kDa subunit of band 4.9, and the 48-kDa
subunit of band 4.9 were positive for 10 of
14 neurobehavioral tests for each (Table 5).
A positive β coefficient for the interaction
term means that subjects with lower back-
phosphorylation levels had larger declines in
neurobehavioral test scores with increasing
blood lead levels than did subjects with
higher back-phosphorylation levels.
For spectrin, 4 of 14 interaction terms
had associated p-values < 0.05, and one other
had an associated p-value < 0.10. For the 52-
kDa subunit of band 4.9, 1 of 14 had an asso-
ciated p-value < 0.05 and one other had an
associated p-value < 0.10. For the 48-kDa
subunit of band 4.9, 3 of 14 interaction terms
had associated p-values < 0.05, and 2 others
had associated p-values < 0.10. The signs of
the β coefﬁcients for all borderline or statisti-
cally signiﬁcant interaction terms were posi-
tive. The results indicated that higher blood
lead levels were only associated with worse
neurobehavioral test scores among subjects
with lower back-phosphorylation levels, or
correspondingly, higher in vivo PKC activity. 
Significant effect modification by back-
phosphorylation levels was mainly observed in
the cognitive domains of manual dexterity
and psychomotor function. In these domains,
blood lead was a statistically signiﬁcant pre-
dictor of worse neurobehavioral test scores
only among subjects with low back-phos-
phorylation levels (Figure 1). 
Discussion
This study was designed to assess associa-
tions of in vivo PKC activity with neurobe-
havioral test scores in current lead workers.
PKC activity, as assessed with the back-
phosphorylation assay, was not associated
with neurobehavioral test scores. However,
PKC activity modified the relationship
between blood lead levels and test scores, the
ﬁrst evidence in humans, albeit indirect, that
PKC may play a role in the neurobehavioral
effects of lead. A large body of experimental
evidence already suggests that PKC is an
important target for lead and is involved in
the mechanism of the neurotoxicity of lead.
The 212 subjects reported herein were a
consecutive sample from 803 lead workers
enrolled in a 4-year prospective study. In
cross-sectional analysis of the 803 subjects,
blood lead was a stronger and more consistent
predictor of neurobehavioral test scores than
was tibia lead or DMSA-chelatable lead (21).
In the subset of 212 subjects, blood lead was
also a consistent predictor of lower neurobe-
havioral test scores (Table 4). However, after
accounting for in vivo PKC activity in the
effect modiﬁcation models, blood lead only
predicted lower neurobehavioral test scores
among subjects with lower in vitro back-phos-
phorylation levels, and thus higher in vivo
PKC activity. The associated p-values for
these relationships were < 0.10 for 5, 2, and 5
of 14 comparisons for back-phosphorylation
levels of spectrin and the 52-kDa and 48-kDa
subunits of band 4.9, respectively, clustered in
the domains of manual dexterity and psy-
chomotor function. Although this evidence is
not overwhelming because of the large num-
ber of associations that were evaluated, we feel
these observations are unlikely to be due to
chance. No such associations were observed
with tibia lead, ZPP, and exposure duration
(data not shown). 
Calcium-dependent PKCs, the presumed
target of lead, are found in erythrocytes and
the brain. Erythrocyte membrane proteins
are also present in the brain (3,39). Spectrin
is found in mouse brain membranes and
undergoes phosphorylation (40), and band
4.9 is also found in the nervous system and
in rod photoreceptor cells (41). Extensive
experimental evidence also documents the
interactions between lead and calcium, espe-
cially as relevant to PKC and regulation of
nervous system functions (15,18,42–44). It
would be expected that mechanisms that
inﬂuence PKC in the brain and erythrocytes
are similar, and thus protein phosphorylation
in erythrocytes could be a surrogate measure
of PKC activity in the brain or, more speciﬁ-
cally, of phosphorylation of similar proteins
in the central nervous system. However, this
discussion must be considered to be specula-
tive because, to our knowledge, no studies
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Table 2. Summary of neurobehavioral test scores in 212 Korean lead workers, 1998. 
Domain, neurobehavioral test Score Min–Max Mean ± SD
Executive abilities
Digit symbol substitution Number correct 9–91 45.9 ± 16.5
Trail Making A Seconds 19–278 52.3 ± 26.6
Trail Making B Seconds 38–312 104.0 ± 43.5
Pegboard, assembly Number of pieces 50–160 106.4 ± 18.3
Psychomotor
Simple reaction time (mean) Milliseconds 0.20–0.78 0.31 ± 0.07
Simple reaction time (SD) Root MSD 0.02–0.35 0.08 ± 0.05
Manual dexterity
Pegboard, dominant hand Number of pieces 30–57 44.2 ± 5.0
Pegboard, nondominant hand Number of pieces 29–60 43.4 ± 5.2
Pegboard, both hands Number of pieces 19–45 34.5 ± 4.6
Pursuit Aiming II Number of dots 65–356 180.2 ± 42.5
Verbal memory/learning, digit span  Number correct 2–22 10.4 ± 3.7
Visual memory, Benton Visual Retention Scale Number correct 3–10 7.7 ± 1.5
Intelligence, colored progressive matrices Number correct 9–36 25.2 ± 6.0
Neuropsychiatric, CES-D Number of rank 0–46 12.1 ± 7.6
Abbreviations: Max, maximum; Min, minimum; MSD, mean square deviation.
Table 3. Pearson’s correlation coefficients between back-phosphorylation levels and neurobehavioral
test scores in 212 Korean lead workers, 1998. 
Back-phosphorylation
Domain, neurobehavioral testa Spectrin 52 kDa 48 kDa
Executive abilities
Digit symbol substitution –0.01 –0.01 –0.01
Trail Making A 0.01 0.02 –0.01
Trail Making B –0.06 0.02 0.05
Pegboard, assembly –0.15* 0.04 0.02
Psychomotor
Simple reaction time (mean) –0.06 0.03 0.01
Simple reaction time (SD) –0.04 0.05 0.04
Manual dexterity
Pegboard, dominant hand –0.19** 0.01 0.01
Pegboard, nondominant hand –0.10 0.08 0.03
Pegboard, both hands –0.13 0.04 0.03
Pursuit Aiming II –0.05 –0.01 –0.02
Verbal memory/learning, digit span  0.01 0.02 0.07
Visual memory, Benton Visual Retention Scale 0.04 –0.08 –0.07
Intelligence, colored progressive matrices –0.03 –0.01 –0.01
Neuropsychiatric, CES–D 0.04 0.08 0.07
aNeurobehavioral tests were standardized for the performance direction such that a negative correlation coefficient
indicates worse performance with increasing back-phosphorylation levels. *p < 0.05; **p < 0.01.have directly compared the function and
activity of PKC in the brain and erythrocytes.
In our study, in vivo PKC activity, as mea-
sured by back-phosphorylation levels, was not
directly associated with neurobehavioral test
scores and did not substantially change the β
coefﬁcients for blood lead when added to the
regression models. This indicates that PKC
activity is unlikely to be in the direct causal
pathway between lead dose and neurobehav-
ioral test scores (45). However, when effect
modiﬁcation was evaluated, PKC activity was
observed to modify the relationship between
blood lead levels and neurobehavioral test
scores. These observations suggest that in vivo
PKC activity may identify a subgroup of
individuals more susceptible to the neurobe-
havioral effects of lead, as discussed further
below. Results from an earlier study indicated
that tibia lead and job duration, as measures
of cumulative exposure, were associated with
back-phosphorylation levels, but blood lead
levels were not (20). These contrasting obser-
vations, that cumulative exposure and dose
measures (i.e., tibia lead, job duration) were
associated with PKC activity but that PKC
activity only modified the relationship
between a short-term dose measure (i.e.,
blood lead) and neurobehavioral function,
demonstrate that much is still unknown
about the pools of lead that are assessed by the
different lead biomarkers. Reliance on a single
lead biomarker in epidemiologic studies of
health outcomes would thus not seem to be
an efﬁcient informative strategy.
There are several potential explanations
for the observation that blood lead only
inﬂuenced neurobehavioral test performance
in subjects with high in vivo PKC activity.
First, PKC activity may be a phenotypic
measure of probable underlying genetic vari-
ation in PKC, a measure of the degree to
which factors other than lead, unmeasured
in this study, can inﬂuence PKC activity. In
the presence of lead, there was considerable
variability in PKC activity, even after control-
ling for differences in blood lead levels.
Second, in vitro back-phosphorylation could
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Figure 1. Associations of blood lead with simple
reaction time (mean), adjusted for age, sex, job
duration, and education in 212 Korean lead work-
ers, 1998. Solid (adjusted β = –0.001, p < 0.01) and
dotted (adjusted β = –0.0001, p = 0.92) lines are for
subjects with low and high levels of in vitro back-
phosphorylation of 52-kDa subunit of band 4.9,
dichotomized at the median, respectively. The dif-
ference in the two slopes achieved statistical sig-
niﬁcance (p < 0.05).
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Table 4. Multiple regression results of associations of blood lead levels with neurobehavioral test scores
in 212 Korean lead workers, 1998. 
Domain, neurobehavioral testa β coefﬁcientb SE
Executive abilities
Digit symbol substitution –0.013 0.062
Trail Making A 0.001 0.002
Trail Making B –0.003* 0.002
Pegboard, assembly –0.041 0.034
Psychomotor
Simple reaction time (mean) –0.0005* 0.0003
Simple reaction time (SD) –0.006* 0.003
Manual dexterity
Pegboard, dominant hand –0.021** 0.010
Pegboard, nondominant hand –0.021** 0.010
Pegboard, both hands –0.021** 0.009
Pursuit Aiming II –0.070 0.102
Verbal memory/learning, digit span  0.008 0.019
Visual memory, Benton Visual Retention Scale 0.001 0.009
Intelligence, colored progressive matrices –0.028 0.030
Neuropsychiatric, CES-D 0.001 0.006
aNeurobehavioral tests were standardized for the performance direction such that a negative β coefficient indicates
worse performance with increasing blood lead. bThe β coefﬁcients for the associations of blood lead levels with neu-
robehavioral test scores were adjusted for age, sex, job duration, and education. The units of the coefﬁcients are in units
of neurobehavioral test per µg/dL blood lead. *p < 0.10. **0.05.
Table 5. Multiple regression results of effect modiﬁcation by back-phosphorylation levels dichotomized at the median on associations of blood lead levels with
neurobehavioral test scores in 212 Korean lead workers, 1998. 
Spectrin back-phosphorylation 52 kDa back-phosphorylation 48 kDa back-phosphorylation
Blood lead Interaction Blood lead Interaction Blood lead Interaction
Neurobehavioral in lowb termc in lowb termc in lowb termc
testa β coeff SE β coeff SE β coeff SE β coeff SE β coeff SE β coeff SE
Digit symbol substitution 0.027 0.086 –0.064 0.111 –0.022 0.085 0.019 0.109 0.023 0.087 –0.064 0.111*
Trail making A 0.001 0.003 –0.0001 0.003 0.002 0.003 –0.002 0.003 0.002 0.003 –0.002 0.003
Trail making B –0.004* 0.003 0.002 0.003 –0.003 0.003 –0.0002 0.003 –0.004* 0.003 0.002 0.003
Pegboard, assembly –0.103** 0.047 0.111* 0.061 –0.060 0.047 0.031 0.060 –0.104** 0.045 –1.113* 0.062
Simple reaction time, mean –0.001*** 0.0004 0.001** 0.0005 –0.001*** 0.0004 0.001** 0.0005 –0.001** 0.0004 0.001* 0.0006
Simple reaction time, SD –0.012*** 0.004 0.012** 0.005 –0.010** 0.004 0.008* 0.005 0.011*** 0.004 0.010** 0.005
Pegboard, dominant hand –0.043*** 0.013 0.039** 0.017 –0.031** 0.013 0.017 0.017 –0.044*** 0.013 0.041** 0.017
Pegboard, nondominant hand –0.032** 0.014 0.020 0.018 –0.012 0.013 –0.018 0.017 –0.021 0.014 –0.0006 0.018
Pegboard, both hands –0.040*** 0.012 0.033** 0.015 –0.031*** 0.012 0.018 0.015 –0.040*** 0.012 0.033** 0.015
Pursuit Aiming II, correct –0.003 0.140 –0.142 0.183 –0.045 0.143 –0.050 0.180 –0.058 0.144 –0.028 0.182
Digit span 0.020 0.026 –0.023 0.034 –0.010 0.026 0.034 0.033 –0.013 0.026 0.038 0.034
Benton Visual Retention Scale –0.006 0.012 0.013 0.016 –0.009 0.012 0.018 0.015 –0.012 0.012 0.025 0.015
Colored progressive matrices –0.033 0.042 0.009 0.055 –0.042 0.042 0.025 0.054 –0.038 0.043 0.019 0.055
CES-D –0.003 0.008 0.009 0.010 0.0003 0.008 0.002 0.010 –0.002 0.008 0.005 0.010
aNeurobehavioral tests were standardized for the performance direction such that a negative β coefﬁcient indicates worse performance with increasing blood lead. Four neurobehav-
ioral tests (SD of reaction time, trails A, trails B, and CES-D) were log-transformed to better approximate normality. bβ coefﬁcients for blood lead in subjects with lower back-phosphory-
lation levels. These values are the adjusted slopes of the relationship between blood lead and neurobehavioral test scores in subjects with lower back-phosphorylation levels. All
models were adjusted for age, sex, job duration, and education. Models with spectrin were also adjusted for the amount of spectrin loaded on the gel (spectrin optical density after
stained with Coomassie Brilliant Blue). The units of the beta coefﬁcients are in units of test score per microgram per deciliter of blood lead. cEffect modiﬁcation by back-phosphorylation
was evaluated by adding interaction terms between blood lead and the back-phosphorylation levels, dichotomized at the median. These β coefﬁcients can be added to those in the
lower back-phosphorylation group to derive the adjusted slopes of the relationship between blood lead and neurobehavioral test scores in the higher back-phosphorylation group. The
units of the β coefﬁcients are in units of test score per microgram per deciliter of blood lead. *p < 0.1; **p < 0.05; ***p < 0.01. be a surrogate measure for bioavailable lead,
after lead binding by tissue sites; subjects with
high PKC activity in the presence of lead may
have less efﬁcient binding to proteins that are
not directly inﬂuenced by lead binding, such
as hemoglobin (i.e., lead binds to hemoglobin
but this binding does not affect hemoglobin
levels) (46). Finally, PKC activity could be a
surrogate measure for brain lead levels. Ion
channels and transporters that participate in
cellular homeostasis, including voltage-depen-
dent calcium channels, are regulated, in part,
by PKC (47–49). These channels are involved
in the uptake of calcium by neurons and
across the blood–brain barrier. These chan-
nels are also permeable to lead, and thus lead
may stimulate its own uptake, into the brain
and into neurons, by activating PKC (47).
Subjects with high PKC activity in the pres-
ence of lead may have higher brain lead levels
for a given blood lead level. In these subjects,
blood lead may be a better surrogate for brain
lead levels and thus more highly correlated
with neurobehavioral test scores.
In this cross-sectional study, blood lead
was more closely associated with perfor-
mance decrements in the cognitive domains
of psychomotor function, manual dexterity,
and executive ability than in other domains.
These observations are consistent with those
of earlier cross-sectional studies of occupa-
tionally exposed subjects (50–54).
In summary, in vivo PKC activity,
assessed by back-phosphorylation of erythro-
cyte membrane proteins, was not a predictor
of neurobehavioral deficits in humans with
current occupational lead exposure. However,
in vivo PKC activity did modify the relation-
ship between blood lead levels and neurobe-
havioral test scores. Subjects with high PKC
activity were apparently more susceptible to
the neurobehavioral effects of lead. These data
are the first evidence in humans that PKC
activity may modulate the neurobehavioral
effects of lead. 
REFERENCES AND NOTES
1. Nishizuka Y. The molecular heterogeneity of protein
kinase C and its implications for cellular regulation.
Nature 334:661–665 (1988). 
2. Dekker LV, De Parker PJ. Protein kinase C—a question
of speciﬁcity. Trends Biochem Sci 19:73–77 (1994).
3. Nishizuka Y. Intracelluar signalling by hydrolysis of phos-
pholipid and activation of protein kinase C. Science
258:607–614 (1992).
4. Matthies HJG, Palfrey HC, Hirning LD, Miller RJ. Down
regulation of protein kinase C in neuronal cells: effects on
neurotransmitter release. J Neurosci 7:1198–1206 (1987).
5.  Weiss S, Ellis J, Hendly DD, Lenox RH. Translocation and
activation of protein kinase C in striatal neurons in pri-
mary culture: relationship to phorphol dibutyrate actions
on the inositol phosphate generating system and neuro-
transmitter release. J Neurochem 52:530–536 (1989).
6.  Akers RF, Lovinger DM, Colley D, Linden D, Routenberg A.
Translocation of protein kinase C activity after LTP may
mediate hippocampal synaptic plasticity. Science
231:587–589 (1986).
7.  Routtenberg A. A tale of two contingent protein kinase C
activators: both neutral and acidic lipids regulate synap-
tic plasticity and information storage. Prog Brain Res
89:249–261 (1991).
8.  Shearman MS, Sekiguchi K, Nishizuka Y. Modulation of
ion channel activity: a key function of the protein kinase
C enzyme family. Pharmacol Rev 41:211–247 (1989).
9. Laterra J, Bressler JP, Indurti RR, Belloni-Olivi L, Goldstein
GW. Inhibition of astroglia-induced endothelial differentia-
tion by inorganic lead: a role for protein kinase C. Proc
Natl Acad Sci USA 89:10748–10752 (1992).
10. Chen HH, Ma T, Ho IK. Protein kinase C in rat brain is
altered by developmental lead exposure. Neurochem
Res 24:415–421 (1999). 
11. Wehner JM, Sleight S, Upchurch M. Hippocampal pro-
tein kinase C activity is reduced in poor spatial learners.
Brain Res 523:181–187 (1990).
12. Pascale A, Govoni S, Battaini F. Age-related alteration of
PKC, a key enzyme in memory processes: physiological
and pathological examples. Mol Neurobiol 16:49–62 (1998).
13. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski
HM, Binder LI. Abnormal phosphorylation of the micro-
tubule-associated protein tau (τ) in Alzheimer cytoskeletal
pathology. Proc Natl Acad Sci USA 83:4913–4917 (1986).
14. Saitoh T, Dobkins KR. In vitro phosphorylation of Mr
60,000 protein is elevated in Alzheimer brain. Proc Natl
Acad Sci USA 83:9764–9767 (1986).
15. Markovac J, Goldstein GW. Picomolar concentrations of
lead stimulate brain protein kinase C. Nature 334:71–73
(1988).
16. Schanne FAX, Dowd TL, Gupta RK, Rosen JF. Lead
increases free Ca2+ concentration in cultured osteoblastic
bone cells: simultaneous detection of intracellular free Pb2+
by 19F-NMR. Proc Natl Acad Sci USA 86:5133–5135 (1989).
17. Schanne FAX, Moskal JR, Gupta RK. Effect of lead on
intracellular free calcium ion concentration in a pre-
synaptic neuronal model: 19F-NMR study of NG108-15
cells. Brain Res 503:308–311 (1989).
18. Tomsig JL, Suszkiw JB. Multisite interactions between
Pb2+ and protein kinase C and its role in norepinephrine
release from bovine adrenal chromaffin cells. J
Neurochem 64:2667–2673 (1995).
19. Chen HH, Ma T, Paul IA, Spencer JL, Ho IK. Developmental
lead exposure and two-way active avoidance training alter
the distribution of protein kinase C activity in the rat hip-
pocampus. Neurochem Res 22:1119–1125 (1997).
20. Hwang KY, Schwartz BS, Lee BK, Strickland PT, Todd AC,
Bressler JP. Associations of lead exposure and dose mea-
sures with erythrocyte protein kinase C activity in 212 cur-
rent Korean lead workers. Toxicol Sci 62:280–288 (2001). 
21. Schwartz BS, Lee B-K, Lee G-S, Stewart WF, Lee S-S,
Hwang K-Y, Ahn K-D, Kim Y-B, Bolla KI, Simon D, et al.
Associations of blood lead, dimercaptosuccinic acid-
chelatable lead, and tibial lead with neurobehavioral test
scores in South Korean lead workers. Am J Epidemiol
153:453–464 (2001).
22. Johnson BL, Baker EL, Batawi M, Gilioli R, Haenninen H,
Seppalainen AM, Xintaras C. Prevention of Neurotoxic
Illness in Working Populations. New York:John Wiley
and Sons, 1987.
23. Wechsler D. The Wechsler Adult Intelligence Scale-
Revised Manual. New York:The Psychological Corporation,
1981.
24.  Benton A. Contributions to Neuropsychological
Assessment. New York:Oxford University Press, 1983.
25.  Fleischman EA. Dimensional analysis of psychomotor
abilities. J Exp Psychol 48:437–454 (1954).
26.  Wilkinson RT, Houghton D. Field test of arousal: a
portable reaction timer with data storage. Hum Factors
24:487–493 (1982).
27.  Haaland KY, Cleeland CS, Carr D. Motor performance
after unilateral hemisphere damage in patients with
tumor. Arch Neurol 34:556–559 (1977).
28.  Reitan RM. Validity of the trail making test as an indica-
tion of organic brain damage. Percep Mot Skills 8:271–276
(1958).
29.  Raven J. The Raven Progressive Matrices: a review of
national norming studies and ethnic and socio-economic
variation within the United States. J Educ Meas 16:1–16
(1989).
30. Radloff LS, Rae DS. Susceptibility and precipitating fac-
tors in depression: sex differences and similarities. J
Abnormal Psychol 88:174–181 (1979).
31.  Thomas WJ, Collins TM. Comparison of venipuncture blood
counts with microcapillary measurements in screening for
anemia in one-year-old infant. J Pediatr 101:32–35 (1982).
32.  Kneip TJ, Crable JV. Methods for Biological Monitoring:
A Manual for Assessing Human Exposure to Hazardous
Substances. Washington, DC:American Public Health
Association 1988.
33.  Korean Ministry of Labor. Regulation on Quality Control for
Measurement of Industrial Environment. Announcement
No. 92-18. Seoul, Korea:Korean Ministry of Labor, 1992.
34.  Blumberg WE, Eisinger J, Lamola AA, Zuckerman DM.
Zinc protoporphyrin level in blood determination by a
portable hematoﬂuorometer: a screening device for lead
poisoning. J Lab Clin Med 89:712–723 (1977).
35. Rowe W, Eyster E, Kellner A. Liquid nitrogen preserva-
tion of red blood cells for transfusion: a low glycerol-
rapid freeze procedure. Cryobiology 5:119–128 (1968).
36.  Dodge JT, Mitchell C, Hanahan DJ. The preparation and
chemical characteristics of hemoglobin-free ghosts of
human erythrocytes. Arch Biochem Biophysiol 100:119–130
(1963).
37.  Bradford MM. A rapid sensitive method for the quantitation
of microgram quantities of protein utilizing the principle of
protein-dye binding. Anal Biochem 72:248–254 (1976).
38.  Horne WC, Miettinen H, Marchesi VT. Erythrocyte mem-
brane skeleton phosphoproteins: identification of two
unrelated phosphoproteins in band 4.9. Biochim Biophys
Acta 944:135–143 (1988).
39.  Bennett V. Proteins involved in membrane–cytoskeleton
association in human erythrocytes: spectrin, ankyrin,
and band 3. Methods Enzymol 96:313–324 (1983).
40.  Goodman SR, Zagon IS, Whitﬁeld CF. A spectrin-like pro-
tein from mouse brain membrane: phosphorylation of the
235,000-dalton subunit. Am J Physiol 247:C61–C73 (1984).
41.  Bennett V. The membrane skeleton of human erythro-
cytes and its implication for more complex cells. Ann Rev
Biochem 45:273–304 (1985).
42.  Goldstein GW, Ar D. Lead activates calmodulin sensitive
processes. Life Sci 33:1001–1006 (1983).
43. Kern  M,  Audesirk G. Inorganic lead may inhibit neurite
development in cultured rat hippocampal neurons
through hyperphosphorylation. Toxicol Appl Pharmacol
134:111–123 (1995).
44.  Long GJ, Rosen JF, Schanne FA. Lead activation of protein
kinase C from rat brain. Determination of free calcium,
lead, and zinc by 19F NMR. J Biol Chem 269:834–837 (1994).
45.  Kleinbaum DG, Kupper LL, Morganstern H. Epidemiologic
Research – Principles and Quantitative Methods. New
York:Van Nostrand Reinhold Company, 1982.
46.  Schwartz BS, Lee B-K, Stewart W, Ahn K-D, Kelsey K,
Bressler J. Associations of subtypes of hemoglobin with
δ-aminolevulinic acid dehydratase genotype and dimer-
captosuccinic acid-chelatable lead levels. Arch Environ
Health 52:97–103 (1997). 
47. Simons TJ, Pocock G. Lead enters adrenal medullary cells
through calcium channels. J Neurochem 48:383–389 (1987).
48. Doerner D, Abdel-Latif M, Rogers TB, Alger BE. Protein
kinase C-dependent and independent effects of phorbol
esters on hippocampal calcium channel current. J
Neurosci 10:1699–1706 (1990).
49. Stea A, Soong TW, Snutch TP. Determinants of PKC-
dependent modulation of a family of neuronal calcium
channels. Neuron 15:929–940 (1995).
50.  Valciukas JA, Lilis R, Eisinger J, Blumberg WE, Fischbein
A, Selikoff IJ. Behavioral indicators of lead neurotoxicity:
results of a clinical ﬁeld survey. Int Arch Occup Environ
Health 41:217–236 (1978).
51.  Stollery BT, Banks HA, Broadbent DE, Lee WR. Cognitive
functioning in lead workers. Br J Ind Med 46:698–707
(1989).
52.  Balbus-Kornfeld JM, Stewart W, Bolla KI, Schwartz BS.
Cumulative exposure to inorganic lead and neurobehav-
ioral test performance in adults: an epidemiological
review. Occup Environ Med 52:2–12 (1995).
53.  Baker EL, White RF, Pothier LJ, Berkey, CS, Dinse GE,
Travers PH, Harley JP, Feldman RG. Occupational lead
neurotoxicity: improvement in behavioral effects after
reduction of exposure. Br J Ind Med 42:507–516 (1985). 
54.  Haenninen H, Hernberg S, Mantere P, Vesanto R, Jalkanen
M. Psychological performance of subjects with low expo-
sure to lead. J Occup Med 20:683–689 (1978).
Articles • Hwang et al.
138 VOLUME 110 | NUMBER 2 | February 2002 • Environmental Health Perspectives